Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant.
Trivedi H, Hamdani O, Thomas B, Richard J, Shah K, Raskina K, Zhang L, Madigan A, Fox M, Wander S, Frigault MJ, Alexander B, Srkalovic G. Trivedi H, et al. Among authors: raskina k. Acta Med Acad. 2021 Apr;50(1):209-217. doi: 10.5644/ama2006-124.336. Acta Med Acad. 2021. PMID: 34075774 Free article.
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, Sayegh N, Lin DI, Raskina K, Schrock AB, Severson E, Haberberger JF, Ross JS, Creeden J, Levy MA, Alexander BM, Oxnard GR, Agarwal N. Graf RP, et al. Among authors: raskina k. JAMA Netw Open. 2022 Mar 1;5(3):e225394. doi: 10.1001/jamanetworkopen.2022.5394. JAMA Netw Open. 2022. PMID: 35357449 Free PMC article.
APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
Sammons S, Raskina K, Danziger N, Alder L, Schrock AB, Venstrom JM, Knutson KL, Thompson EA, McGregor K, Sokol E, Chumsri S. Sammons S, et al. Among authors: raskina k. JCO Precis Oncol. 2022 Oct;6:e2200149. doi: 10.1200/PO.22.00149. JCO Precis Oncol. 2022. PMID: 36315915 Free PMC article.
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
Graf RP, Fisher V, Mateo J, Gjoerup OV, Madison RW, Raskina K, Tukachinsky H, Creeden J, Cunningham R, Huang RSP, Mata DA, Ross JS, Oxnard GR, Venstrom JM, Zurita AJ. Graf RP, et al. Among authors: raskina k. Eur Urol. 2022 Jan;81(1):37-47. doi: 10.1016/j.eururo.2021.09.030. Epub 2021 Oct 26. Eur Urol. 2022. PMID: 34716049 Free article.
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J. Zurita AJ, et al. Among authors: raskina k. JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195. JCO Precis Oncol. 2022. PMID: 35820087 Free PMC article.
Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.
Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, Jänne PA. Cheng ML, et al. Among authors: raskina k. JCO Precis Oncol. 2022 Nov;6:e2200382. doi: 10.1200/PO.22.00382. JCO Precis Oncol. 2022. PMID: 36455195 No abstract available.
11 results